• Phen
    link
    fedilink
    arrow-up
    5
    ·
    4 days ago

    My guess is the ones that have prostate cancer.

    • ikt@aussie.zone
      link
      fedilink
      English
      arrow-up
      1
      arrow-down
      1
      ·
      4 days ago

      it says in the article

      The test uses AI to study images of tumours and pick out features invisible to the human eye. The team, funded by Prostate Cancer UK, the Medical Research Council and Artera, trialled the test on biopsy images from more than 1,000 men with high-risk prostate cancer that had not spread.

      The AI test identified the 25% of men in the group most likely to benefit from the abiraterone – for these men, the drug halves the risk of death.

      In the trial, patients received a score – biomarker-positive or -negative – which was compared with their outcomes. For those with biomarker-positive tumours, one in four of the men, abiraterone cut their risk of death after five years from 17% to 9%.

      For those with biomarker-negative tumours, abiraterone cut the risk of death from 7% to 4% – a difference that was not statistically or clinically significant, the team said. These men would benefit from standard therapy alone and be spared unnecessary treatment.